The nested open reading frame in the Epstein-Barr virus nuclear antigen-1 mRNA encodes a protein capable of inhibiting antigen presentation in cis

Molecular Immunology

Volumn 44, Issue 14, 2007, Pages 3588-3596

  Ossevoort, Martine ^a   Zaldumbide, Arnaud ^a   te Velthuis, Aartjan J W ^a   Melchers, Mark ^a   Ressing, Maaike E ^a   Wiertz, Emmanuel J H J ^a   Hoeben, Rob C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antigen; Epstein Barr virus; Fusion protein; Immune evasion; Proteasome

Indexed keywords

BETA GALACTOSIDASE; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 1; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HYBRID PROTEIN; LATENCY ASSOCIATED NUCLEAR ANTIGEN; LATENCY ASSOCIATED NUCLEAR ANTIGEN 1; MESSENGER RNA; PEPTIDE DERIVATIVE; THREONYLPROLYLHISTIDYLPROLYLALANYLARGINYLISOLEUCYLGLYCYLLEUCINE; UNCLASSIFIED DRUG;

ACIDITY; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CIS ISOMER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EMBRYO; EPSTEIN BARR VIRUS; GENE THERAPY; GENETIC CODE; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; TRANSGENE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; BASE SEQUENCE; BETA-GALACTOSIDASE; CELL LINE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; OPEN READING FRAMES; PEPTIDES; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; VIRAL PROTEINS;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4; LANA;

EID: 34248582393     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2007.03.005     Document Type: Article

References (38)

1. Blake N., Lee S., Redchenko I., Thomas W., Steven N., Leese A., Steigerwald-Mullen P., Kurilla M.G., Frappier L., and Rickinson A. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7 (1997) 791-802
2. Blake N.W., Moghaddam A., Rao P., Kaur A., Glickman R., Cho Y.G., Marchini A., Haigh T., Johnson R.P., Rickinson A.B., and Wang F. Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1. J. Virol. 73 (1999) 7381-7389
3. Bochkarev A., Barwell J.A., Pfuetzner R.A., Bochkareva E., Frappier L., and Edwards A.M. Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. Cell 84 (1996) 791-800
4. Fetten J.V., Roy N., and Gilboa E. A frameshift mutation at the NH2 terminus of the nucleoprotein gene does not affect generation of cytotoxic T lymphocyte epitopes. J. Immunol. 147 (1991) 2697-2705
5. Graham F.L., and van der Eb A.J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52 (1973) 456-467
6. Ho O., and Green W.R. Alternative translational products and cryptic T cell epitopes: expecting the unexpected. J. Immunol. 177 (2006) 8283-8289
7. Hoeben R.C., Migchielsen A.A., van der Jagt R.C., van Ormondt H., and van der Eb A.J. Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position. J. Virol. 65 (1991) 904-912
8. Klein G. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 77 (1994) 791-793
9. Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44 (1986) 283-292
10. Kozak M. Recognition of AUG and alternative initiator codons is augmented by G in position +4 but is not generally affected by the nucleotides in positions +5 and +6. EMBO J. 16 (1997) 2482-2492
11. Lammert E., Arnold D., Rammensee H.G., and Schild H. Expression levels of stress protein gp96 are not limiting for major histocompatibility complex class I-restricted antigen presentation. Eur. J. Immunol. 26 (1996) 875-879
12. Lee M.A., Diamond M.E., and Yates J.L. Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus. J. Virol. 73 (1999) 2974-2982
13. Lee S.P., Brooks J.M., Al Jarrah H., Thomas W.A., Haigh T.A., Taylor G.S., Humme S., Schepers A., Hammerschmidt W., Yates J.L., Rickinson A.B., and Blake N.W. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J. Exp. Med. 199 (2004) 1409-1420
14. Levitskaya J., Coram M., Levitsky V., Imreh S., Steigerwald-Mullen P.M., Klein G., Kurilla M.G., and Masucci M.G. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375 (1995) 685-688
15. Levitskaya J., Sharipo A., Leonchiks A., Ciechanover A., and Masucci M.G. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. U.S.A 94 (1997) 12616-12621
16. Macejak D.G., and Sarnow P. Internal initiation of translation mediated by the 5′ leader of a cellular mRNA. Nature 353 (1991) 90-94
17. Malarkannan S., Afkarian M., and Shastri N. A rare cryptic translation product is presented by Kb major histocompatibility complex class I molecule to alloreactive T cells. J. Exp. Med. 182 (1995) 1739-1750
18. Mayrand S.M., and Green W.R. Non-traditionally derived CTL epitopes: exceptions that prove the rules?. Immunol. Today 19 (1998) 551-556
19. Mayrand S.M., Schwarz D.A., and Green W.R. An alternative translational reading frame encodes an immunodominant retroviral CTL determinant expressed by an immunodeficiency-causing retrovirus. J. Immunol. 160 (1998) 39-50
20. McBratney S., Chen C.Y., and Sarnow P. Internal initiation of translation. Curr. Opin. Cell Biol. 5 (1993) 961-965
21. Miller A.D., Eckner R.J., Jolly D.J., Friedmann T., and Verma I.M. Expression of a retrovirus encoding human HPRT in mice. Science 225 (1984) 630-632
22. Ossevoort M., Visser B.M., van den Wollenberg D.J., van der Voort E.I., Offringa R., Melief C.J., Toes R.E., and Hoeben R.C. Creation of immune 'stealth' genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1. Gene Ther. 10 (2003) 2020-2028
23. Ossevoort M., Zaldumbide A., Cramer S.J., van der Voort E.I., Toes R.E., and Hoeben R.C. Characterization of an immuno 'stealth' derivative of the herpes simplex virus thymidine-kinase gene. Cancer Gene Ther. 13 (2006) 584-591
24. Price J., Turner D., and Cepko C. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc. Natl. Acad. Sci. U.S.A 84 (1987) 156-160
25. Rowe M., Lear A.L., Croom-Carter D., Davies A.H., and Rickinson A.B. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J. Virol. 66 (1992) 122-131
26. Schwab S.R., Li K.C., Kang C., and Shastri N. Constitutive display of cryptic translation products by MHC class I molecules. Science 301 (2003) 1367-1371
27. Shah W.A., Ambinder R.F., Hayward G.S., and Hayward S.D. Binding of EBNA-1 to DNA creates a protease-resistant domain that encompasses the DNA recognition and dimerization functions. J. Virol. 66 (1992) 3355-3362
28. Sharipo A., Imreh M., Leonchiks A., Branden C., and Masucci M.G. cis-Inhibition of proteasomal degradation by viral repeats: impact of length and amino acid composition. FEBS Lett. 499 (2001) 137-142
29. Sharipo A., Imreh M., Leonchiks A., Imreh S., and Masucci M.G. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat. Med. 4 (1998) 939-944
30. Shastri N., Nguyen V., and Gonzalez F. Major histocompatibility class I molecules can present cryptic translation products to T-cells. J. Biol. Chem. 270 (1995) 1088-1091
31. Smith D.B., and Johnson K.S. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 67 (1988) 31-40
32. Tellam J., Connolly G., Green K.J., Miles J.J., Moss D.J., Burrows S.R., and Khanna R. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J. Exp. Med. 199 (2004) 1421-1431
33. Tellam J., Sherritt M., Thomson S., Tellam R., Moss D., Burrows S., Wiertz E., and Khanna R. Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition. J. Biol. Chem. 276 (2001) 33353-33360
34. Voo K.S., Fu T., Wang H.Y., Tellam J., Heslop H.E., Brenner M.K., Rooney C.M., and Wang R.F. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J. Exp. Med. 199 (2004) 459-470
35. Wang R.F., Parkhurst M.R., Kawakami Y., Robbins P.F., and Rosenberg S.A. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J. Exp. Med. 183 (1996) 1131-1140
36. Weiss R.B., Dunn D.M., Atkins J.F., and Gesteland R.F. Slippery runs, shifty stops, backward steps, and forward hops: -2, -1, +1, +2, +5, and +6 ribosomal frameshifting. Cold Spring Harb. Symp. Quant. Biol. 52 (1987) 687-693
37. Yates J.L., Warren N., and Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313 (1985) 812-815
38. Zaldumbide A., Ossevoort M., Wiertz E.J., and Hoeben R.C. In cis inhibition of antigen processing by the latency-associated nuclear antigen I of Kaposi Sarcoma Herpes virus. Mol. Immunol. 44 (2007) 1352-1360